Entry |
|
Symbol |
MAP2K2
|
Name |
(RefSeq) mitogen-activated protein kinase kinase 2
|
KO |
|
Organism |
csab Chlorocebus sabaeus (green monkey)
|
Pathway |
csab01521 | EGFR tyrosine kinase inhibitor resistance |
csab04550 | Signaling pathways regulating pluripotency of stem cells |
csab04613 | Neutrophil extracellular trap formation |
csab04620 | Toll-like receptor signaling pathway |
csab04650 | Natural killer cell mediated cytotoxicity |
csab04935 | Growth hormone synthesis, secretion and action |
csab05022 | Pathways of neurodegeneration - multiple diseases |
csab05166 | Human T-cell leukemia virus 1 infection |
csab05167 | Kaposi sarcoma-associated herpesvirus infection |
csab05170 | Human immunodeficiency virus 1 infection |
csab05207 | Chemical carcinogenesis - receptor activation |
csab05208 | Chemical carcinogenesis - reactive oxygen species |
csab05230 | Central carbon metabolism in cancer |
csab05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
|
Brite |
KEGG Orthology (KO) [BR:csab00001]
09130 Environmental Information Processing
09132 Signal transduction
04010 MAPK signaling pathway
103233717 (MAP2K2)
04012 ErbB signaling pathway
103233717 (MAP2K2)
04014 Ras signaling pathway
103233717 (MAP2K2)
04015 Rap1 signaling pathway
103233717 (MAP2K2)
04370 VEGF signaling pathway
103233717 (MAP2K2)
04371 Apelin signaling pathway
103233717 (MAP2K2)
04066 HIF-1 signaling pathway
103233717 (MAP2K2)
04068 FoxO signaling pathway
103233717 (MAP2K2)
04072 Phospholipase D signaling pathway
103233717 (MAP2K2)
04071 Sphingolipid signaling pathway
103233717 (MAP2K2)
04024 cAMP signaling pathway
103233717 (MAP2K2)
04022 cGMP-PKG signaling pathway
103233717 (MAP2K2)
04151 PI3K-Akt signaling pathway
103233717 (MAP2K2)
04150 mTOR signaling pathway
103233717 (MAP2K2)
09140 Cellular Processes
09141 Transport and catabolism
04140 Autophagy - animal
103233717 (MAP2K2)
04148 Efferocytosis
103233717 (MAP2K2)
09143 Cell growth and death
04210 Apoptosis
103233717 (MAP2K2)
04218 Cellular senescence
103233717 (MAP2K2)
09144 Cellular community - eukaryotes
04540 Gap junction
103233717 (MAP2K2)
04550 Signaling pathways regulating pluripotency of stem cells
103233717 (MAP2K2)
09142 Cell motility
04810 Regulation of actin cytoskeleton
103233717 (MAP2K2)
09150 Organismal Systems
09151 Immune system
04613 Neutrophil extracellular trap formation
103233717 (MAP2K2)
04620 Toll-like receptor signaling pathway
103233717 (MAP2K2)
04650 Natural killer cell mediated cytotoxicity
103233717 (MAP2K2)
04660 T cell receptor signaling pathway
103233717 (MAP2K2)
04662 B cell receptor signaling pathway
103233717 (MAP2K2)
04664 Fc epsilon RI signaling pathway
103233717 (MAP2K2)
09152 Endocrine system
04910 Insulin signaling pathway
103233717 (MAP2K2)
04929 GnRH secretion
103233717 (MAP2K2)
04912 GnRH signaling pathway
103233717 (MAP2K2)
04915 Estrogen signaling pathway
103233717 (MAP2K2)
04917 Prolactin signaling pathway
103233717 (MAP2K2)
04921 Oxytocin signaling pathway
103233717 (MAP2K2)
04926 Relaxin signaling pathway
103233717 (MAP2K2)
04935 Growth hormone synthesis, secretion and action
103233717 (MAP2K2)
04919 Thyroid hormone signaling pathway
103233717 (MAP2K2)
04916 Melanogenesis
103233717 (MAP2K2)
09153 Circulatory system
04270 Vascular smooth muscle contraction
103233717 (MAP2K2)
09156 Nervous system
04720 Long-term potentiation
103233717 (MAP2K2)
04730 Long-term depression
103233717 (MAP2K2)
04722 Neurotrophin signaling pathway
103233717 (MAP2K2)
09160 Human Diseases
09161 Cancer: overview
05200 Pathways in cancer
103233717 (MAP2K2)
05206 MicroRNAs in cancer
103233717 (MAP2K2)
05205 Proteoglycans in cancer
103233717 (MAP2K2)
05207 Chemical carcinogenesis - receptor activation
103233717 (MAP2K2)
05208 Chemical carcinogenesis - reactive oxygen species
103233717 (MAP2K2)
05230 Central carbon metabolism in cancer
103233717 (MAP2K2)
05231 Choline metabolism in cancer
103233717 (MAP2K2)
05235 PD-L1 expression and PD-1 checkpoint pathway in cancer
103233717 (MAP2K2)
09162 Cancer: specific types
05210 Colorectal cancer
103233717 (MAP2K2)
05225 Hepatocellular carcinoma
103233717 (MAP2K2)
05226 Gastric cancer
103233717 (MAP2K2)
05214 Glioma
103233717 (MAP2K2)
05216 Thyroid cancer
103233717 (MAP2K2)
05221 Acute myeloid leukemia
103233717 (MAP2K2)
05220 Chronic myeloid leukemia
103233717 (MAP2K2)
05218 Melanoma
103233717 (MAP2K2)
05211 Renal cell carcinoma
103233717 (MAP2K2)
05219 Bladder cancer
103233717 (MAP2K2)
05215 Prostate cancer
103233717 (MAP2K2)
05213 Endometrial cancer
103233717 (MAP2K2)
05224 Breast cancer
103233717 (MAP2K2)
05223 Non-small cell lung cancer
103233717 (MAP2K2)
09172 Infectious disease: viral
05166 Human T-cell leukemia virus 1 infection
103233717 (MAP2K2)
05170 Human immunodeficiency virus 1 infection
103233717 (MAP2K2)
05161 Hepatitis B
103233717 (MAP2K2)
05160 Hepatitis C
103233717 (MAP2K2)
05164 Influenza A
103233717 (MAP2K2)
05163 Human cytomegalovirus infection
103233717 (MAP2K2)
05167 Kaposi sarcoma-associated herpesvirus infection
103233717 (MAP2K2)
05165 Human papillomavirus infection
103233717 (MAP2K2)
09171 Infectious disease: bacterial
05132 Salmonella infection
103233717 (MAP2K2)
05135 Yersinia infection
103233717 (MAP2K2)
09164 Neurodegenerative disease
05010 Alzheimer disease
103233717 (MAP2K2)
05022 Pathways of neurodegeneration - multiple diseases
103233717 (MAP2K2)
09167 Endocrine and metabolic disease
04934 Cushing syndrome
103233717 (MAP2K2)
09176 Drug resistance: antineoplastic
01521 EGFR tyrosine kinase inhibitor resistance
103233717 (MAP2K2)
01522 Endocrine resistance
103233717 (MAP2K2)
09180 Brite Hierarchies
09181 Protein families: metabolism
01001 Protein kinases [BR:csab01001]
103233717 (MAP2K2)
Enzymes [BR:csab01000]
2. Transferases
2.7 Transferring phosphorus-containing groups
2.7.12 Dual-specificity kinases (those acting on Ser/Thr and Tyr residues)
2.7.12.2 mitogen-activated protein kinase kinase
103233717 (MAP2K2)
Protein kinases [BR:csab01001]
Serine/threonine kinases: STE group
STE7 family
103233717 (MAP2K2)
|
SSDB |
|
Motif |
|
Other DBs |
|
LinkDB |
|
Position |
6:complement(3848441..3881367)
|
AA seq |
400 aa
MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQ
KAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQ
VLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRG
LAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQ
GTHYSVQSDIWSMGLSLVELAIGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRP
PGRPISGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADL
KMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV |
NT seq |
1203 nt +upstreamnt +downstreamnt
atgctggcccggaggaagccggtgctgccggcgctcaccatcaaccctaccatcgccgag
ggcccgtcccctaccagcgagggcgcctccgaggcaaacctggtggacctgcagaagaag
ctggaggagctggaacttgacgagcagcagaagaagcgtctggaagcctttctcacccag
aaagccaaggtcggcgaactcaaagacgatgacttcgaaaggatctcagagctgggcgcg
ggcaatggcggggtggtcaccaaagtccagcacagaccctcaggcctcatcatggccagg
aagctgatccaccttgagatcaagccggccatccggaaccagatcatccgcgagctgcag
gtcctgcatgagtgcaactcgccatacatcgtgggcttctacggggccttctacagcgac
ggggagatcagcatctgcatggagcacatggatggcggctccctggaccaggtgctgaag
gaggccaagaggatccccgaggagatcctggggaaagtcagcattgcggttctccgcggc
ttggcgtatctccgagagaagcaccagatcatgcaccgagatgtgaagccctccaacatc
cttgtgaactccagaggggagatcaagctgtgtgacttcggggtgagcggccagctcatc
gactccatggccaactccttcgtgggcacacgctcctacatggctccggagcggttgcag
ggcacacattactcggtgcagtcggacatctggagcatgggcctgtccctggtggagctg
gccatcggaaggtaccccatccccccgcccgacgccaaggagctggaggccatctttggc
aggccagtggtcgacggggaagaaggagagcctcacagcatctcgcctcggccgagaccc
cctgggcgccccatcagcggtcacgggatggacagccggcccgccatggccatcttcgaa
ctgctggactatattgtgaatgagccgcctcctaagctgcccaacggtgtgttcaccccc
gacttccaggagtttgtcaataaatgcctcatcaagaacccagcagagcgggcagacctg
aagatgctcacgaaccacaccttcatcaagcggtccgaggtggaagaagtggattttgcc
gggtggttgtgtaaaaccctgcgactgaaccagcccggcacacccacgcgcaccgccgtg
tga |